188 related articles for article (PubMed ID: 17186200)
1. Assessment of the pharmaceutical market in Poland after accession to the European Union.
Willert PL
Eur J Health Econ; 2007 Dec; 8(4):347-57. PubMed ID: 17186200
[TBL] [Abstract][Full Text] [Related]
2. [Impact Reimbursement Act on the pharmaceutical market in Poland].
Giermaziak W
Pol Merkur Lekarski; 2014 Apr; 36(214):270-3. PubMed ID: 24868902
[TBL] [Abstract][Full Text] [Related]
3. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
Adamini S; Maarse H; Versluis E; Light DW
J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
[TBL] [Abstract][Full Text] [Related]
4. [Drugs in the European Union: the health-market complex].
Antoñanzas F; Rodríguez R; Sacristán JA; Illa R
Gac Sanit; 2005; 19(2):151-67. PubMed ID: 15860163
[TBL] [Abstract][Full Text] [Related]
5. Drug Policy in Poland.
Jahnz-Różyk K; Kawalec P; Malinowski K; Czok K
Value Health Reg Issues; 2017 Sep; 13():23-26. PubMed ID: 29073983
[TBL] [Abstract][Full Text] [Related]
6. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
[TBL] [Abstract][Full Text] [Related]
7. Health improvement in Poland is contingent on continued extensive tobacco control measures.
Zatoński W; Zatoński M; Przewoźniak K
Ann Agric Environ Med; 2013; 20(2):405-11. PubMed ID: 23772599
[TBL] [Abstract][Full Text] [Related]
8. The single market for pharmaceuticals in the European Union in light of European Court of Justice rulings.
Kanavos P
Pharmacoeconomics; 2000 Dec; 18(6):523-32. PubMed ID: 11227392
[TBL] [Abstract][Full Text] [Related]
9. [An analysis of the pharmaceuticals market in Vietnam].
Simonet D
Sante; 2001; 11(3):155-60. PubMed ID: 11641078
[TBL] [Abstract][Full Text] [Related]
10. An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case.
Ades F; Senterre C; Zardavas D; de Azambuja E; Popescu R; Parent F; Piccart M
Eur J Cancer; 2014 Dec; 50(18):3089-97. PubMed ID: 25446375
[TBL] [Abstract][Full Text] [Related]
11. Using market-exclusivity incentives to promote pharmaceutical innovation.
Kesselheim AS
N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231
[No Abstract] [Full Text] [Related]
12. Pharmaceutical regulation in the European Community: barriers to single market integration.
Orzack LH; Kaitin KI; Lasagna L
J Health Polit Policy Law; 1992; 17(4):847-68. PubMed ID: 1299692
[TBL] [Abstract][Full Text] [Related]
13. Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries.
Kolasa K; Kalo Z; Zah V; Dolezal T
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):283-7. PubMed ID: 22812552
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical markets regulation overview of the selected European Union countries.
Pogorzelczyk K; Synoweć J; Robakowska M; Ślęzak D; Holajn P; Robakowski P; Żuratyński P; Nadolny K
Wiad Lek; 2018; 71(7):1404-1408. PubMed ID: 30448818
[TBL] [Abstract][Full Text] [Related]
15. Implications of the accession of the Republic of Croatia to the European Union for Croatian health care system.
Ostojić R; Bilas V; Franc S
Coll Antropol; 2012 Sep; 36(3):717-27. PubMed ID: 23213925
[TBL] [Abstract][Full Text] [Related]
16. Future European health care: cost containment, health care reform and scientific progress in drug research.
Emilien G
Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
[TBL] [Abstract][Full Text] [Related]
17. Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenarios.
Gress S; Niebuhr D; May U; Wasem J
Pharmacoeconomics; 2007; 25(6):443-54. PubMed ID: 17523750
[TBL] [Abstract][Full Text] [Related]
18. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
19. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
20. Are national drug expenditure control policies compatible with a single European market?
Rovira J
Pharmacoeconomics; 1996; 10 Suppl 2():4-13. PubMed ID: 10172762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
